Edmond DE Rothschild Holding S.A. Purchases Shares of 2,330,000 Geron Corporation $GERN

Edmond DE Rothschild Holding S.A. purchased a new stake in shares of Geron Corporation (NASDAQ:GERN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 2,330,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,982,000.

A number of other institutional investors also recently modified their holdings of the company. Renaissance Technologies LLC grew its stake in Geron by 144.1% in the first quarter. Renaissance Technologies LLC now owns 1,799,521 shares of the biopharmaceutical company’s stock worth $2,681,000 after purchasing an additional 1,062,355 shares during the period. Janus Henderson Group PLC boosted its holdings in Geron by 826.7% in the first quarter. Janus Henderson Group PLC now owns 2,218,196 shares of the biopharmaceutical company’s stock worth $3,304,000 after acquiring an additional 1,978,839 shares in the last quarter. Eversept Partners LP boosted its stake in Geron by 6.7% in the 1st quarter. Eversept Partners LP now owns 18,834,883 shares of the biopharmaceutical company’s stock worth $28,064,000 after purchasing an additional 1,174,900 shares in the last quarter. Candriam S.C.A. raised its holdings in Geron by 38.1% in the first quarter. Candriam S.C.A. now owns 3,921,476 shares of the biopharmaceutical company’s stock worth $5,843,000 after buying an additional 1,081,992 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in Geron by 3.6% in the 4th quarter. Vanguard Group Inc. now owns 35,660,969 shares of the biopharmaceutical company’s stock worth $47,072,000 after acquiring an additional 1,237,844 shares during the last quarter. 73.71% of the stock is currently owned by hedge funds and other institutional investors.

Geron Price Performance

NASDAQ:GERN opened at $1.55 on Friday. The business’s 50-day simple moving average is $1.41 and its two-hundred day simple moving average is $1.48. Geron Corporation has a 52 week low of $1.04 and a 52 week high of $2.01. The stock has a market cap of $995.83 million, a PE ratio of -14.09 and a beta of 0.61. The company has a quick ratio of 5.16, a current ratio of 6.91 and a debt-to-equity ratio of 0.55.

Geron (NASDAQ:GERN) last released its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Geron had a negative return on equity of 24.48% and a negative net margin of 34.17%.The business had revenue of $57.48 million for the quarter, compared to analysts’ expectations of $55.30 million. As a group, analysts forecast that Geron Corporation will post -0.04 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Geron from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $4.00.

Geron Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.